Jubilant Pharmova has appointed Daniel J. O`Connor as CEO of Jubilant Therapeutics Inc. step down subsidiary of the company. Powered by Capital Market - Live News

The board of Jubilant Pharmova at its meeting held on 31 October 2025 has approved the Grant of 1,506 Stock Options/ Restricted Stock Units (RSUs) to the eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.Powered by Capital Market - Live News

Net profit of Jubilant Pharmova rose 17.02% to Rs 120.30 crore in the quarter ended September 2025 as against Rs 102.80 crore during the previous quarter ended September 2024. Sales rose 12.38% to Rs 1957.80 crore in the quarter ended September 2025 as against Rs 1742.20 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1957.801742.20 12 OPM %17.4316.61 - PBDT300.90250.00 20 PBT196.10158.60 24 NP120.30102.80 17 Powered by Capital Market - Live News

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 31 October 2025.Powered by Capital Market - Live News

Jubilant Pharmova announced today that Jubilant HollisterStier LLC (JHS)�a wholly owned subsidiary and a leading North American pharmaceutical contract manufacturer, specialising in sterile injectables and serving top global innovator pharma companies�successfully launched its New Sterile Fill & Finish line, third at its Spokane Manufacturing Facility in Washington, US. The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new Line. This milestone denotes a significant advancement in Jubilant HollisterStier`s multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility. The New Line features advanced isolator technology designed to deliver enhanced sterility assurance, throughput and operational precision. Built to meet the highest global regulatory standards, the New Line significantly enhances the Company`s ability to support complex injectable programs across a broad range of therapeutic areas. The US$ 132 million investment towards this New Third Line, reflects the Company`s long-term commitment to innovation, quality and supply chain resilience. Together with the commissioning of its upcoming Fourth Line, JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility in the US. This strategic investment further reinforces JHS` leadership in domestic US pharmaceutical manufacturing. By expanding its infrastructure and increasing onshore capacity, the Company is contributing to US national health security and helping to reduce reliance on offshore supply chains� delivering a more resilient and agile pharmaceutical manufacturing ecosystem. Powered by Capital Market - Live News